Visceral fat / GH-axis comparison
Tesamorelin vs CJC-1295 (with DAC)
Tesamorelin has strong indication-specific Phase III VAT evidence; CJC-1295 mainly has early endocrine target-engagement studies.
At a glance
Tesamorelin
CJC-1295 (with DAC)
Human evidence
Tesamorelin has strong evidence for its narrow HIV-associated abdominal-fat indication. A randomized HIV/NAFLD study also reduced liver fat substantially, while a small 2025 Phase II cognitive trial did not show significant between-group cognitive benefit.
Small early human studies show sustained GH and IGF-I elevation after CJC-1295 with DAC, establishing endocrine target engagement but not body-composition, recovery or anti-ageing efficacy.
Research focus
Excess abdominal visceral fat in adults with HIV and lipodystrophy
Growth-hormone axis research
Regulatory status
FDA-licensed Egrifta formulations are indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy; not a general weight-loss approval.
Not FDA-approved; FDA lists CJC-1295 among substances with significant safety concerns in compounding.
Route / formulation
Research-market tesamorelin is not automatically equivalent to authorised Egrifta products.
CJC-1295 with DAC is not interchangeable with informal 'CJC without DAC' products.
No appropriate head-to-head trial Tesamorelin has strong indication-specific Phase III VAT evidence; CJC-1295 mainly has early endocrine target-engagement studies.